Epi+Gen CHD™
Three-year Coronary Heart Disease Event Risk Assessment
What is Epi+Gen CHD™?
Epi+Gen CHD™ is a clinical blood test, available by prescription only, that assesses the three-year risk of a coronary heart disease event, including a heart attack and sudden death. It evaluates a targeted panel of three epigenetic and five genetic biomarkers. By applying artificial intelligence, this test predicts with high sensitivity a patient’s risk of having a coronary heart disease event within the next three years.
Epi+Gen CHD™ allows providers to sensitively assess risk of a coronary heart disease event regardless of the presence and severity of traditional risk factors. With re-testing, the DNA methylation biomarkers of Epi+Gen CHD™ have demonstrated to change in response to intervention. This test is non-invasive and does not require fasting.
2x
more sensitive than conventional risk calculators
Non-Invasive, No Radiation, No Fasting
Understanding the Epi+Gen CHD™ Risk Score
Epi+Gen CHD™ delivers a precise risk score informed by the patient’s molecular profile.
Low
Borderline
7.1%
Intermediate
High
This example illustrates the Epi+Gen CHD™ clinical report, showing a patient’s three-year risk of a coronary heart disease event as borderline at 7.1%. The report also compares the patient’s risk to peers of the same sex and age, while providing a detailed explanation of the common drivers of heart disease.
Epi+Gen CHD™ Is Intended for Patients Who:
Rx Only FSA/HSA Eligible
Are between 35 to 75 years old
Have not been diagnosed with heart disease
Have not had an abnormal stress test
Have not experienced a heart attack or cardiac surgery
Have not had a bone marrow transplant
No history of angina (chest pain), especially with exertion
No Radiation ● No Fasting ● Compatible with Telemedicine
Quantify Heart Attack Risk at the Molecular Level With Epi+Gen CHD™
- Dogan MV, Knight S, Dogan TK, Knowlton KU, Philibert R. External validation of integrated genetic-epigenetic biomarkers for predicting incident coronary heart disease. Epigenomics. 2021;13(14):1137-1152. doi:10.2217/epi-2021-0123